
Graham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma
The HemOnc Pulse
00:00
Relapsed GVD - What's Next?
checkpoint inhibitors, many of us use them at relapsed. And we saw Alison Moskowitz present data on Pembroke GVD a year or so ago now. It was relatively small numbers, about 35 patients, very high response rate. I think it was an 89% overall response. The vast majority got to autographed. Their one year PFS was 90%. So, you know, it's a one year follow up. But of course, most relapses happened within a year. That was quite clear from the etheria study, much larger study done several years ago now.
Transcript
Play full episode